Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland
CHICAGO, IL / ACCESSWIRE / July 25, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its wholly-owned subsidiary, Decahedron Ltd ("Decahedron"), has successfully submitted its tender to supply the National Health Service (NHS) in Scotland with its antimicrobial wash, C-Scrub Wash Chlorhexidine 4% ("C-Scrub").
Cosmos Health公司(以下简称“该公司”)(纳斯达克股票代码:COSM)是一家全球综合性、垂直整合的医疗保健集团,从事创新的研发、拥有专有药品和营养品品牌、生产和分销医疗保健产品,以及运营远程医疗平台。该公司的全资子公司Decahedron有限公司(以下简称“Decahedron”)已成功提交招标书,以供应苏格兰国民保健服务(National Health Service,NHS)其抗菌洗涤剂C-Scrub Wash Chlorhexidine 4%(以下简称“C-Scrub”)。
Decahedron has been invited to participate in the NHS Scotland tender for "Antiseptic Solutions and Hand Hygiene Products." Participation in this tender process is conducted on an invitation-only basis. The Company has successfully submitted its tender to supply the NHS in Scotland with its C-Scrub antimicrobial wash in 250ml and 500ml pack sizes.
Decahedron已被邀请参加NHS Scotland关于“抗菌洗涤产品和手部卫生产品”的招标。该招标流程的参与是基于邀请的。公司已成功提交招标书,以在250毫升和500毫升包装尺寸下为NHS Scotland提供其C-Scrub抗菌洗涤剂。
C-Scrub, with 4% chlorhexidine gluconate, offers immediate and prolonged antimicrobial action for up to 6 hours, even in the presence of biological fluids. Ideal for routine hand disinfection, it targets bacteria, viruses, and fungi without promoting resistance. Suitable for iodine-sensitive users, it includes emollients for skin health and is cosmetically friendly. C-Scrub is perfect for healthcare environments, including hospitals, clinics, surgery rooms, emergency departments, wards, ICUs, and other medical facilities.
C-Scrub含有4%的氯己定葡萄糖酸盐,能够提供长达6小时的立即和持久的抗菌作用,即使在生物体液存在的情况下也能表现良好。它适用于常规手部消毒,可以靶向各种细菌、病毒和真菌,而不会产生抗药性。它适合碘过敏的用户,含有润肤成分有助于皮肤保健,且是美容友好的。C-Scrub非常适合医疗环境,包括医院、诊所、手术室、急诊科、病房、重症监护室和其他医疗设施。
Cosmos Health expects to participate in additional tenders across the United Kingdom, including those with NHS England.
Cosmos Health有望参与英国包括NHS England在内的其他招标活动。
According to Grand View Research, the antibacterial products market in the UK is expected to grow from $656.5 million in 2020 to $733.0 million by 2028, reflecting a compound annual growth rate (CAGR) of 1.4%.
据Grand View Research统计,英国抗菌产品市场从2020年的656.5万美元增长至2028年的7,330万美元,在反应复合年增长率(CAGR)为1.4%。
Suhel Bhutawala, Director of Decahedron, stated: "We are delighted to have been invited to participate in the tender for antiseptic solutions and hand hygiene products. Our team has successfully submitted our proposal, and we eagerly look forward to supplying NHS Scotland with our C-Scrub antimicrobial wash."
Decahedron的董事Suhel Bhutawala表示:“我们很高兴被邀请参加抗菌洗涤产品和手部卫生产品的投标活动。我们的团队已成功提交了我们的建议,我们非常期待向苏格兰国民保健服务提供我们的C-Scrub抗菌洗涤剂。”
Greg Siokas, CEO of Cosmos Health, stated: "We are pleased to announce that we have successfully submitted our tender for C-Scrub and look forward to becoming a trusted supplier to NHS Scotland. The UK market is of great significance to Cosmos, and we are eager to participate in additional tenders for our products, including those for NHS England."
Cosmos Health的首席执行官Greg Siokas表示:“我们很高兴地宣布我们已经成功提交了C-Scrub的招标书,并期待成为苏格兰国民保健服务的信任供应商。对Cosmos来说,英国市场具有重要意义,我们非常期望参与国家医疗保健服务英格兰在内的关于我们产品的更多招标活动。”
About the NHS
国民保健服务(National Health Service,NHS)是英格兰的公共医疗保健系统之一,是全球最大的单一支付者医疗保健系统之一,由政府通过一般纳税和国民保险费用的补充资金资助,受卫生和社会护理部(Department of Health and Social Care)监管。它为英格兰和其他英国地区的所有合法居民提供医疗保健服务,大多数人群的大多数服务都是免费的。此外,NHS还通过国家卫生保健研究所(National Institute for Health and Care Research,NIHR)进行研究。
The National Health Service (NHS) is the publicly funded healthcare system in England and one of the four National Health Service systems in the United Kingdom. It is one of the world's largest single-payer healthcare systems. Funded primarily by the government through general taxation and supplemented by National Insurance contributions, the NHS is overseen by the Department of Health and Social Care. It provides healthcare services to all legal residents of England and residents from other UK regions, with most services being free at the point of use for most individuals. Additionally, the NHS conducts research through the National Institute for Health and Care Research (NIHR).
保守派党派表示,最新资讯显示,英国初创企业由于担心2016年英国脱欧带来的不确定性,其在全国范围投入等值于27亿美元的投资,这使得华尔街主要股指纳斯达克(NASDAQ)特别关注英国的新的IPO市场。
About Cosmos Health Inc.
Cosmos Health Inc.(纳斯达克:COSM)成立于2009年,总部位于内华达州,是一家全球健康医疗集团公司。公司拥有一系列专有药品和保健品牌,包括Sky Premium Life,Mediterranation,bio-bebe和C-Sept。公司的子公司Cana Laboratories S.A.获得欧洲GMP许可和欧洲药品管理局认证,生产医药品、食品补充剂、化妆品、生物灭菌剂和医疗设备等产品,并经营欧盟内的销售。此外,Cosmos Health还通过希腊和英国的子公司向零售药店和批发经销商销售广泛的药品和非处方药品,包括品牌仿制药和OTC药品。此外,该公司还与人工智能药物再利用技术合作,专注于研发针对肥胖症、糖尿病和癌症等主要健康障碍的研发合作,并专注于研发新的专利营养保健品、特殊植物提取物、专有复合仿制药和创新非处方药品。Cosmos Health还通过收购总部位于德克萨斯州的ZipDoctor,Inc进入了远程医疗领域。公司正在全球范围内扩张,并在希腊的塞萨洛尼基和雅典、英国的哈洛等地设有办事处和配送中心。 更多信息请访问公司网站:,以及LinkedIn和X。
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe and C-Sept. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at , , , , as well as LinkedIn and X.
Cosmos Health Inc.(纳斯达克:COSM)于2009年在内华达州成立,是一家多元化、垂直整合的全球保健集团。公司拥有一系列专有的药品和营养保健品牌,包括Sky Premium Life、Mediterranation、bio-bebe和C-Sept。通过其子公司Cana Laboratories S.A.的许可,该公司在欧洲联盟范围内制造药品、食品补充剂、化妆品、生物杀灭剂和医疗设备,并遵守欧洲药品管理局(EMA)的认证的欧洲良好生产规范(GMP)。Cosmos Health还通过其在希腊和英国的子公司向零售药店和批发经销商分销包括品牌通用名和场外交易药物在内的各类药品和光合生物。此外,公司已经建立了针对肥胖症、糖尿病和癌症等主要健康障碍的研发合作关系,并获得了人工智能药物再利用技术增强,专注于新型专利营养保健品、特制根提取物、专有复杂通用名和创新场外交易产品的研发。Cosmos Health还通过收购位于美国德克萨斯州的ZipDoctor,Inc.进入了远程医疗领域。拥有全球分销平台,该公司目前正在欧洲、亚洲和北美进行扩张,并在希腊的塞萨洛尼基和雅典,以及英国的哈洛设有办事处和分销中心。更多信息可在, , , ,以及LinkedIn和X上获得。
Forward-Looking Statements
前瞻性声明
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Cosmos Health Inc.("公司")在本新闻稿中所述的事项中除了包含历史信息外,还可能包含根据1933年修订的《证券法》第27A条和1934年修订的《证券交易法》第21E条的前瞻性陈述。前瞻性声明涉及未知的风险和不确定性,可能因以下原因之一而对讨论的事项产生个别或实质性影响,这在公司的控制范围之外,包括但不限于公司筹集足够融资实施其业务计划的能力,新冠病毒大流行和乌克兰战争对公司业务、运营和经济的影响以及公司成功开发和商业化自有产品和技术的能力。读者应该注意不要过度依赖这些前瞻性声明,因为实际结果可能与本新闻稿中所述的前瞻性声明不同。读者应该注意阅读证券交易委员会的风险因素,该委员会在其网站上(www.sec.gov)提供了这些信息。本公司不承担更新或修订任何前瞻性陈述的义务。
Investor Relations Contact:
投资者关系联系人:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
资讯来源:Cosmos Health Inc.